National Academies Review of Compounded Hormone Therapy

The U.S. Food and Drug Administration summarizes the National Academies Review of compounded bioidentical hormone therapy. This article reads the FDA's two key sentences on it for Berkeley Heights readers.
The wording under review
The first sentence, from the U.S. Food and Drug Administration: "Based on its research and analysis, NASEM determined there was a lack of rigorous evidence of safety and effectiveness from well-designed or properly controlled clinical studies."
The second, from the same agency: "Given the lack of high-quality clinical evidence and minimal oversight of cBHT, NASEM concluded that their wide-spread use poses a public health concern."
NASEM is the review body's abbreviation in the FDA's text. The abbreviation cBHT stands, in the subject of this review, for compounded bioidentical hormone therapy.
Clause by clause
The first sentence says "lack of rigorous evidence," and it names two things the evidence is missing for: safety and effectiveness. The studies it wants are "well-designed or properly controlled," so the gap is in study quality and not in a single result.
The second sentence adds a second shortfall, "minimal oversight." Its conclusion is that "wide-spread use poses a public health concern." The word is "concern."
Where pitches go past the text
A pitch that calls compounded hormones proven is outside both sentences, since they report a lack of rigorous evidence of safety and effectiveness.
The reverse overreach is also worth marking. The sentences say evidence is lacking. They do not say each compounded product was shown to cause harm. A literal reader keeps both readings out of the sentence.
For background, WebMD's explainer, Bioidentical Hormone Therapy: What It Is, is a published treatment of the wider topic. On the agency's own site, the general menopause page shows how the same agency words the surrounding subject for consumers. The parent hub, Bioidentical Hormones for Women: Uses and Safety, places this review beside the other documents.
The question the wording leaves open
The sentences describe missing rigorous studies. They do not say what a well-designed study of a compounded product would have to show.
Before agreeing to a compounded hormone, ask the prescriber whether any controlled clinical study supports that exact product, and ask to read it.